Bio

Parth Kumar is a fellow in the Stanford University Nephrology Fellowship Program. Dr. Kumar holds a B.A. in Molecular and Cell Biology from UC Berkeley and an M.D. with Distinction from UCSF School of Medicine. He completed his Internal Medicine Residency at UC Irvine, where he was recognized as the Intern Teacher of the Year in 2022. Dr. Kumar's research interests span health care innovation and translational medicine, such as integrating 3D printing into clinical settings to aid patient education, evaluating novel medical devices. His past work includes the study "Evaluating the use of Radioactive Analogs of Doxorubicin for Quantifying ChemoFilter binding and Whole Body PET/MRI Biodistribution," leading to him being recognized as one of the JVIR Editor's Honorees: Distinguished Laboratory Investigations in 2022.

Clinical Focus

  • Fellow
  • nephrology
  • medical devices

Professional Education

  • Residency, UC Irvine, Internal Medicine (2024)
  • MD, UCSF (2021)
  • BA, UC Berkeley (2016)

Additional Info

Graduate and Fellowship Programs

All Publications

  • Shiga Toxin-Directed Complement-Mediated Hemolytic Uremic Syndrome Treated with Eculizumab American Society of Nephrology Kumar, P., Siu, M., Tantisattamo, E., Ferrey, A. J. 2023: 1060

    View details for DOI 10.1681/ASN.20233411S11060a

  • Evaluating Radioactive Analogs of Doxorubicin to Quantify ChemoFilter Binding and Whole-Body Positron Emission Tomography/Magnetic Resonance Imaging for Drug Biodistribution. Journal of vascular and interventional radiology : JVIR Kumar, P., Yee, C., Blecha, J. E., Hayes, T. R., Kilbride, B. F., Stillson, C., Losey, A. D., Mastria, E., Jordan, C. D., Huynh, T. L., Moore, T., Wilson, M. W., VanBrocklin, H. F., Hetts, S. W. 2022; 33 (6): 687-694

    Abstract

    To evaluate radiolabeled doxorubicin (Dox) analogs as tracers of baseline Dox biodistribution in vivo during hepatic intra-arterial chemotherapy and to assess the efficacy of ChemoFilter devices to bind Dox in vitro.In an in vitro static experiment, [fluorine-18]N-succinimidyl 4-fluorobenzoate ([18F]SFB) and [fluorine-18]fluorobenzoyl-doxorubicin ([18F]FB-Dox) were added to a beaker containing a filter material (Dowex cation exchange resin, single-stranded DNA (ssDNA) resin, or sulfonated polymer coated mesh). In an in vitro flow model, [18F]FB-Dox was added into a Dox solution in phosphate-buffered saline, and the solution flowed via a syringe column containing the filter materials. In an in vitro flow experiment, using micro-positron emission tomography (PET), images were taken as [18F]SFB and [18F]FB-Dox moved through a phantom. For in vivo biodistribution testing, a catheter was placed into the common hepatic artery of a swine, and [18F]FB-Dox was infused over 30 seconds. A 10-minute dynamic image and three 20-minute static images were acquired using 3T PET/MR imaging.In the in vitro static experiment, [18F]FB-Dox demonstrated 76.7%, 88.0%, and 52.4% binding to the Dowex resin, ssDNA resin, and coated mesh, respectively. In the in vitro flow model, the first-pass binding of [18F]FB-Dox to the Dowex resin, ssDNA resin, and coated mesh was 76.7%, 74.2%, and 76.2%, respectively, and the total bound fraction was 80.9%, 84.6%, and 79.9%, respectively. In the in vitro flow experiment using micro-PET, the phantom demonstrated a greater amount of [18F]FB-Dox bound to both filter cartridges than of the control [18F]SFB. In in vivo biodistribution testing, the first 10 minutes depicted [18F]FB-Dox moving through the right upper quadrant of the abdomen. A region-of-interest analysis showed that the relative amount increased by 2.97 times in the gallbladder and 1.08 times in the kidney. The amount decreased by 0.74 times in the brain and 0.57 times in the heart.[18F]FB-Dox can be used to assess Dox binding to ChemoFilters as well as in vivo biodistribution. This sets the stage for the evaluation of ChemoFilter effectiveness in reducing systemic toxicity from intra-arterial chemotherapy.

    View details for DOI 10.1016/j.jvir.2022.03.007

    View details for PubMedID 35301127

    View details for PubMedCentralID PMC9156544

  • Morphological and Transcriptional Responses to CRISPRi Knockdown of Essential Genes in Escherichia coli. mBio Silvis, M. R., Rajendram, M., Shi, H., Osadnik, H., Gray, A. N., Cesar, S., Peters, J. M., Hearne, C. C., Kumar, P., Todor, H., Huang, K. C., Gross, C. A. 2021: e0256121

    Abstract

    CRISPR interference (CRISPRi) has facilitated the study of essential genes in diverse organisms using both high-throughput and targeted approaches. Despite the promise of this technique, no comprehensive arrayed CRISPRi library targeting essential genes exists for the model bacterium Escherichia coli, or for any Gram-negative species. Here, we built and characterized such a library. Each of the 500 strains in our E. coli library contains an inducible, chromosomally integrated single guide RNA (sgRNA) targeting an essential (or selected nonessential) gene and can be mated with a pseudo-Hfr donor strain carrying a dcas9 cassette to create a CRISPRi knockdown strain. Using this system, we built an arrayed library of CRISPRi strains and performed population and single-cell growth and morphology measurements as well as targeted follow-up experiments. These studies found that inhibiting translation causes an extended lag phase, identified new modulators of cell morphology, and revealed that the morphogene mreB is subject to transcriptional feedback regulation, which is critical for the maintenance of morphology. Our findings highlight canonical and noncanonical roles for essential genes in numerous aspects of cellular homeostasis. IMPORTANCE Essential genes make up only 5 to 10% of the genetic complement in most organisms but occupy much of their protein synthesis and account for almost all antibiotic targets. Despite the importance of essential genes, their intractability has, until recently, hampered efforts to study them. CRISPRi has facilitated the study of essential genes by allowing inducible and titratable depletion. However, all large-scale CRISPRi studies in Gram-negative bacteria thus far have used plasmids to express CRISPRi components and have been constructed in pools, limiting their utility for targeted assays and complicating the determination of antibiotic effects. Here, we use a modular method to construct an arrayed library of chromosomally integrated CRISPRi strains targeting the essential genes of the model bacterium Escherichia coli. This library enables targeted studies of essential gene depletions and high-throughput determination of antibiotic targets and facilitates studies targeting the outer membrane, an essential component that serves as the major barrier to antibiotics.

    View details for DOI 10.1128/mBio.02561-21

    View details for PubMedID 34634934

  • 13th International HHT Scientific Conference : June 12-16, 2019, San Juan, Puerto Rico. Angiogenesis 2019; 22 (4): 585-631

    View details for DOI 10.1007/s10456-019-09686-w

    View details for PubMedID 31691880

  • Abstracts from the 2017 Society of General Internal Medicine Annual Meeting. Journal of general internal medicine 2017; 32 (Suppl 2): 83-808

    View details for DOI 10.1007/s11606-017-4028-8

    View details for PubMedID 28397154

    View details for PubMedCentralID PMC5391321

https://orcid.org/0000-0002-5091-0999